Business Wire

BEYOND Developments Unveils EVERMORE Masterplan on Marjan Beach in Ras Al Khaimah

18.2.2026 07:00:00 CET | Business Wire | Press Release

Share

BEYOND Developments unveiled EVERMORE, its first fully masterplanned destination on Marjan Beach in Ras Al Khaimah, marking the opening chapter of BEYOND’s 2026 growth strategy and a bold expansion beyond Dubai.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217969384/en/

EVERMORE by BEYOND Developments - The Essence of French Living at Marjan Beach, Ras Al Khaimah (Photo: AETOSWire)

Strategically located opposite Wynn Al Marjan Island, EVERMORE is a long-term lifestyle and residential waterfront district framed by the sea and Marjan’s future botanical garden. The masterplan blends French classical elegance with contemporary architecture, integrated nature, and lifestyle-focused placemaking, creating a distinctive setting where architecture, hospitality, and public spaces harmonize with water and greenery.

Mahdi Amjad, Founder and Executive Chairman of BEYOND Developments, said: “Ras Al Khaimah is witnessing a new phase of development, underpinned by disciplined planning, rising global relevance and the long-term vision of its leadership whose support has been instrumental in enabling our entry into the emirate.”

“The new masterplan, EVERMORE, spansmore than 7 million square feet of gross floor area with a projected gross development value exceeding AED 25 billion. It brings together an exceptional coastal destination with world-class design, hospitality, and community-led placemaking. It stands as a defining milestone in our journey, marking our first expansion outside Dubai and first destination in Ras Al Khaimah, and reflecting our commitment to contributing meaningfully to the Emirate’s urban, tourism, and economic evolution,” added Amjad.

Abdulla Al Abdouli, the Group CEO of Marjan, said: “EVERMORE represents a significant milestone for Marjan Beach and Ras Al Khaimah. As the second-largest masterplan within our portfolio, it strengthens Marjan Beach’s evolution as a destination where lifestyle, hospitality, and nature come together to shape the future of the emirate.”

“We are proud to partner with BEYOND on this transformative development, which will serve as a defining anchor for Marjan Beach and a key chapter in Ras Al Khaimah’s real estate and tourism growth story. This masterplan adds a meaningful new layer to the beach’s evolution and strengthens its positioning as a global lifestyle and investment destination,” added Al Abdouli.

Anchored by 250,000 sq. metres of landscaped open spaces, including a central botanical garden, EVERMORE is designed as a fully pedestrian masterplan. Shaded walkways and green connections link the botanical garden to 3.5 kilometres of accessible beachfront, reinforcing walkability, wellbeing and human-centric living. The destination integrates residential, hospitality and retail components, including 1 million sq. ft. of hospitality and branded residential offerings, alongside a festival and events plaza, botanical souks, an F&B village and a continuous beachfront promenade, together forming a self-sustained cultural and leisure district.

The design draws on French classical architecture, reimagining proportion, symmetry, and spatial order through a contemporary lens. Cascading buildings maximize sea and landscape views, while landscaped greenery, shaded pathways, and pedestrian bridges ensure comfort, privacy, and seamless connectivity.

EVERMORE is designed to endure across generations, contributing meaningfully to the Ras Al Khaimah Vision 2030 and the emirate’s evolving urban and economic narrative.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20260217969384/en/

Contacts

Wael Sarieddine
PR Manager
Tel. + 971551077949
wael.sarieddine@beyondproperties.ae

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye